idelalisib

01/01/2018 - "The inhibitor of PI3k-δ, idelalisib, has been shown to be effective in the treatment of chronic lymphocytic leukemia. "
01/01/2016 - "Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). "
11/01/2023 - "Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group."
10/01/2020 - "Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial."
01/01/2019 - "Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials."

09/01/2023 - "Idelalisib is a first-in-class PI3Kδ inhibitor effective in patients with B-cell lymphoid malignancies. "
01/01/2017 - "The less differentiated phenotype and improved engraftment of CAL-101 T cells resulted in stronger antitumor immunity compared to traditionally expanded CD8+ T cells in both tumor models. "
10/01/2016 - "The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3Kδ inhibitor idelalisib in B-cell malignancies. "
08/16/2016 - "Despite the clinical success of the first selective PI3Kδ inhibitor, CAL-101, inhibition of PI3Kδ itself did not show too much cytotoxic efficacy against cancer cells. "
01/01/2017 - "This study aimed to investigate anti-cancer effects of Idelalisib, a potent PI3K-δ inhibitor, in a panel of hematological cell lines. "

01/01/2017 - "Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy."
01/01/2018 - "Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma."
11/15/2017 - "Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report."
01/27/2022 - "Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study."
11/01/2022 - "Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients."

04/01/2016 - "Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. "
01/01/2016 - "[Grave diarrhea associated with idelalisib administration]."
12/01/2015 - "All 11 patients were receiving idelalisib and underwent colonoscopy for the evaluation of diarrhea. "
12/01/2015 - "Twenty-three (46%) patients experienced diarrhea during treatment with idelalisib, including 8 with severe symptoms (≥7 stools/d above baseline and/or requiring hospitalization). "
11/01/2020 - "In this small sample of patients with metastatic PDAC, exposure to idelalisib resulted in safety findings consistent with previous studies, with reduced diarrhea/colitis."

05/01/2014 - "The PI3Kδ inhibitor idelalisib was effective in heavily pretreated patients with mantle cell lymphoma."
05/29/2014 - "Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). "
05/29/2014 - "A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)."
02/01/2022 - "P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib."
01/01/2017 - "Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma."